A patent victory under threat

The stunning reaffirmation of India’s commitment to prevent evergreening of patent monopolies on medicines has been widely celebrated. The Supreme Court has upheld the rejection of a secondary patent on Novartis’ cancer medicine, Glivec.

Read Full Story>>